Waters Corporation (NYSE: WAT) and IMU Biosciences have announced a strategic partnership to accelerate the development of IMU's next-generation AI-powered High Definition (HD) Immunology platform. The collaboration aims to decode the immune system and enable a paradigm shift in how diseases are understood, diagnosed, and treated.
Partnership Details and Technologies
The partnership integrates Waters Biosciences' advanced flow cytometry and single-cell technologies—including BD FACSDiscover Cell Analyzers, BD flow cytometry reagents with BD Horizon Real Dyes, BD Rhapsody Instruments, and BD OMICS-One WTA Next Assay and Protein Panels—with IMU's HD analysis and proprietary AI and machine learning analytics. This combination allows reproducible, real-time characterization of the immune system, turning complex immune data into actionable insights for discovery, translational, and clinical research.
Unprecedented Immune Data Collection
IMU's platform measures the immune system in unprecedented detail, delivering more than 100 million data points from a single blood sample through HD multiomic analysis combined with machine learning. IMU is building the world's largest immune dataset, leveraging extensive patient samples and population-wide clinical data to establish a universal standard for immune profiling.
According to John Baker, Ph.D., Chief Executive Officer of IMU Biosciences, “Waters Biosciences was the clear partner to help IMU Biosciences scale our HD Immunology platform to the level required for true population-wide immune mapping, given their longstanding leadership in high-throughput flow cytometry and single-cell technologies. Our world-leading immune dataset and proprietary AI analytics will unlock the potential of Waters’ best-in-class analytical instruments, accelerating our work to decode the immune system and power the next generation of precision medicine.”
Impact on Precision Medicine and Drug Development
Steve Conly, Senior Vice President of Waters Biosciences, added, “By partnering with IMU Biosciences, we are helping to build the most detailed picture of the human immune system ever assembled at clinical scale. Together, our companies’ cutting-edge technologies across instruments, reagents, and informatics will help advance immune profiling into a standardized, universally accessible clinical tool that can be used across the continuum of care for cancer and other diseases, supporting smarter, faster drug development.”
The collaboration supports IMU's expansion of its immune dataset through large-scale studies, establishing a new standard for immune profiling. This partnership is expected to drive breakthroughs in early diagnosis, monitoring, and precision medicine for cancer and other diseases.
